
Placebo (n=123)
Dupilumab 300 mg q4w (n=122)
Dupilumab 100/200 mg q2w (n=122)




IGA 0/1 Overall
Proportion of patients (%)
100
90
80
70
60
50
40
30
20
10
0
0
4
8
12
16
Week
33%
30%
11%

FIG. 1A


Placebo (n=61)
Dupilumab 300 mg q4w (n=61)
Dupilumab 100 mg q2w (n=63)



IGA 0/1:
Baseline Weight <30 kg
Proportion of patients (%)
100
90
80
70
60
50
40
30
20
10
0
0
4
8
12
16
Week
30%
21%
13%

FIG. 1B



Placebo (n=123)
Dupilumab 300 mg q4w (n=122)
Dupilumab 100/200 mg q2w (n=122)
EASI-75:
Overall
70%
67%
27%
Proportion of patients (%)
Week
0
4
8
12
16
0
10
20
30
40
50
60
70
80
90
100

FIG. 1D



Placebo (n=62)
Dupilumab 300 mg q4w (n=61)
Dupilumab 200 mg q2w (n=59)
IGA 0/1:
Baseline Weight ≥30 kg
39%
36%
10%
Proportion of patients (%)
Week
0
4
8
12
16
0
10
20
30
40
50
60
70
80
90
100

FIG. 1C



Placebo (n=62)
Dupilumab 300 mg q4w (n=61)
Dupilumab 200 mg q2w (n=59)
EASI-75:
Baseline Weight ≥30 kg
75%
64%
26%
Proportion of patients (%)
Week
0
4
8
12
16
0
10
20
30
40
50
60
70
80
90
100

FIG. 1F



Placebo (n=61)
Dupilumab 300 mg q4w (n=61)
Dupilumab 100 mg q2w (n=63)
EASI-75:
Baseline Weight <30 kg
75%
60%
28%
Proportion of patients (%)
Week
0
4
8
12
16
0
10
20
30
40
50
60
70
80
90
100

FIG. 1E



Placebo (n=123)
Dupilumab 300 mg q4w (n=122)
Dupilumab 100/200 mg q2w (n=122)
LS Percent Change EASI:
Overall
Proportion of patients (%)
0
-10
-20
-30
-40
-50
-60
-70
-80
-90
-100
0
4
8
12
16
Week
-49%
-78%
-82%

FIG. 1G



Placebo (n=61)
Dupilumab 300 mg q4w (n=61)
Dupilumab 100 mg q2w (n=63)
LS Percent Change EASI:
Baseline Weight <30kg
Proportion of patients (%)
0
-10
-20
-30
-40
-50
-60
-70
-80
-90
-100
0
4
8
12
16
Week
-49%
-77%
-84%

FIG. 1H



LS Percent Change EASI:
Baseline Weight ≥30kg
Placebo (n=62)
Dupilumab 300 mg q4w (n=61)
Dupilumab 200 mg q2w (n=59)
-48%
-80%
-80%
Proportion of patients (%)
0
-10
-20
-30
-40
-50
-60
-70
-80
-90
-100
0
4
8
12
16
Week

FIG. 1I



Proportion of patients with ≥3-point improvement from baseline over time: baseline weight <30 kg
Proportion of patients (%)
Week
68%
62%
18%
<30 kg Placebo (n=61)
<30 kg Dupilumab 300 mg q4w (n=61)
<30 kg Dupilumab 100 mg q2w (n=63)

FIG. 2B



Proportion of patients with ≥3-point improvementfrom baseline over time: Overall
Proportion of patients (%)
Week
68%
60%
21%
Placebo (n=123)
Dupilumab 300 mg q4w (n=121)
Dupilumab 100/200 mg q2w (n=120)

FIG. 2A



Proportion of patients with ≥4-point improvement from baseline over time: Overall
Proportion of patients (%)
Week
58%
51%
12%
Placebo (n=123)
Dupilumab 300 mg q4w (n=120)
Dupilumab 100/200 mg q2w (n=120)

FIG. 2D



Proportion of patients with ≥3-point improvement from baseline over time: baseline weight ≥ 30 kg
Proportion of patients (%)
Week
67%
58%
24%
≥ 30 kg Placebo (n=62)
≥ 30 kg Dupilumab 300 mg q4w (n=61)
≥ 30 kg Dupilumab 200 mg q2w (n=59)

FIG. 2C



Proportion of patients with ≥4-point improvement from baseline over time: baseline weight ≥ 30 kg
Proportion of patients (%)
Week
61%
48%
13%
≥ 30 kg Placebo (n=62)
≥ 30 kg Dupilumab 300 mg q4w (n=61)
≥ 30 kg Dupilumab 200 mg q2w (n=59)

FIG. 2F



Proportion of patients with ≥4-point improvement from baseline over time: baseline weight < 30 kg
Proportion of patients (%)
Week
56%
54%
12%
<30 kg Placebo (n=61)
<30 kg Dupilumab 300 mg q4w (n=61)
<30 kg Dupilumab 100 mg q2w (n=63)

FIG. 2E



Total SCORAD over time, LS mean (± SE)
100
80
60
40
20
0
0
2
4
6
8
10
12
14
16
Week
51.3
29.5***
27.4***
Placebo+TCS (n = 123)
Dupilumab 300 mg q4w+TCS (n = 122)
Dupilumab 100/200 mg q2w + TCS (n = 122)

FIG. 3



Phase 2a
Mean (±SD) dupilumab concentration (mg/L)
1000
100
10
1
0.1
0.01
LLOQ/2
0
4
8
12
16
20
Study week
Dupilumab 2 mg/kg
Dupilumab 4 mg/kg

FIG. 4A



Phase 3 OLE
Mean (±SD) dupilumab concentration (mg/L)
1000
100
10
1
0.1
0.01
LLOQ/2
0 4 8 12 16 20 24 28 32 36 40 44 48
Study week
Dupilumab 2 mg/kg
Dupilumab 4 mg/kg

FIG. 4B



Dupilumab 2 mg/kg
Dupilumab 4 mg/kg
LLOQ/2
Mean (+SD) dupilumab concentration (mg/L)
1000
100
10
1
0.1
0.01
0
4
8
12
16
20
Study week

FIG. 5A



Mean (+SD) dupilumab concentration (mg/L)
1000
100
10
1
0.1
0.01
LLOQ/2
0
4
8
12
16
20
24
28
32
36
40
44
48
Study week
Dupilumab 2 mg/kg
Dupilumab 4 mg/kg

FIG. 5B